TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05591066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PFC I-PASS Intervention
Description: Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PFC I-PASS+ Intervention
Description: PFC I-PASS+ builds on PFC I-PASS to make it better and focus on the special needs of patients who speak languages other than English. PFC I-PASS+ includes all parts of PFC I-PASS plus having interpreters during and after rounds, cultural humility training, and provider communication skills training.
Study: NCT06468072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expressivity protocol for children with autism
Description: The activities proposed by this protocol stimulate different expressive skills, which are often lacking in people with autism. For this reason, the protocol is based on the strengthening of the following skills: perception of the body in movement in the space (4 sessions), the expressiveness of the body in its entirety (4 sessions), breathing and the use of the voice to express emotions in relation to the environment (4 sessions), rhythm and movement, to develop motor coordination and the expressiveness of movements (4 sessions). The protocol consists of 16 sessions: a weekly group session lasting one hour.

Intervention type: OTHER
Group type: OTHER
Intervention: Expressivity protocol for non-autistic children
Description: The activities proposed by this protocol stimulate different expressive skills. The protocol is based on the strengthening of the following skills: perception of the body in movement in space (4 sessions), the expressiveness of the body in its entirety (4 sessions), breathing and the use of the voice to express emotions in relation to the environment (4 sessions), rhythm and movement, to develop motor coordination and the expressiveness of movements (4 sessions). The protocol consists of 16 sessions: a weekly group session lasting one hour.
Study: NCT05787535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine + Cyclophosphamide
Description: Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HRYZ-T101 TCR-T Cell
Description: On day 1, the TCR-T cells will be administered one time.
Study: NCT05285566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: 106mg (8 mL) subcutaneous injection injected after costal cartilage harvest

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine
Description: 8 mL of 1% lidocaine with 1:100,000 of epinephrine into costal cartilage wound site
Study: NCT05720494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP441
Description: Oral study drug administered for up to 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo administered for up to 4 weeks
Study: NCT05629234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib (dose range of 40 mg to 240 mg orally, once daily)
Study: NCT06646159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REThink Intervention
Description: At its core, the REThink game consists of seven levels, each focusing on a specific emotion-regulation skill crucial for emotional health. The game's story is based on the RETMAN character which helps the player fight the power of the Irrationalizer who personalizes irrational beliefs. The game is based on cognitive-behavioral psychotherapy - the unified protocol (Barlow et al., 2004) and well-supported Rational Emotive Behavioral Therapy (Ellis, 1995). Each level is composed of three sublevels, increasing in difficulty, and also has an embedded validated assessment system (composed of a sublevel for each level; David, Tomoiaga \& Fodor, 2024), and can function as a standalone intervention.
Study: NCT06410703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN1012
Description: CAN1012 IT injection every three weeks (Q3W), Toripalimab will be administered at the approved dose of 240mg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN1012
Description: CAN1012 IT injection every three weeks (Q3W), Toripalimab will be administered at the approved dose of 240mg IV Q3W
Study: NCT06463652

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Description: Cervical cerclage using the McDonald technique under anaesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Description: Cyclogest® 200mg, Actavis, United Kingdom, applied once daily at bedtime.
Study: NCT06099951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab + FOLFOXIRI
Description: Starting from day 0, the patient will receive 8 cycles of FOLFOXIRI regimen at specific intervals. The FOLFOXIRI regimen includes irinotecan 165mg/m2, oxaliplatin 85mg/m2, calcium folinate 200mg/m2 on day 1, followed by continuous intravenous infusion of 5-FU 2400mg/m2/day for 46 hours. This regimen is repeated every 14 days.During radiotherapy (Monday to Friday), the patient will receive capecitabine 1650mg/m2/day orally twice daily. Serplulimab immunotherapy will be administered every 2 weeks during the FOLFOXIRI neoadjuvant chemotherapy period. Serplulimab will be given on the first day and the 14th day of radiotherapy, dissolved in 100ml normal saline and administered intravenously over 30-60 minutes at a dose of 200mg.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy
Study: NCT06121960

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: spirometry
Description: Inclusion visit:~Performing spirometry.~Visit 2 (in the month following the inclusion visit):~Induction of a self-induced cognitive trance by the participant; performance of spirometry before, during the trance then 8 minutes after the end of the trance Actimetry during trance
Study: NCT05319561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic Use Report
Description: The Antibiotic Use Report uses both text and graphics to communicate successes and improvement opportunities specific to the VAMC for which it is prepared. The graphs summarize overall antibiotic use over the previous year, with additional information regarding use of broad- and narrow-spectrum agents. Further, each Antibiotic Use Report compares or benchmarks the individual VAMC for which it is prepared to other VAMCs in the same Medical Complexity Group. This approach adapts and expands peer comparison, which has proven effective at reducing inappropriate antibiotic use in outpatient settings.
Study: NCT06463652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone
Description: Cyclogest® 200mg, Actavis, United Kingdom, applied once daily at bedtime.
Study: NCT05748158

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight loss
Description: A behavioral lifestyle program, up to 20 weeks in duration, based on interventions shown to be successful for weight loss such as the Diabetes Prevention Program (DPP), Action for Health in Diabetes (Look AHEAD), and Comprehensive Assessment of the Long-term Effects of Reducing Intake of Energy Study (CALERIE). Weekly sessions, led by experienced interventionists, will provide education and behavioral strategies for weight loss focused an energy-reduced diet and physical activity.~Participants must meet the following milestones to continue in the study:~* ≥ 2% weight loss anytime between 28 and 34 days after the start of the intervention~* ≥ 5% weight loss anytime between 140 and 146 days after the start of the intervention~* ≥ 7% weight loss by the end of 37 weeks~After achieving ≥7% weight loss followed by weight stability, participants are observed, without further intervention, for 52 weeks.
Study: NCT05496959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu-177 PNT2002
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT06648590

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The experimental phase of this study lasts 56 days and each subject will have 3 follow-up visits(d1、d28、d56).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The experimental phase of this study lasts 56 days and each subject will have 3 follow-up visits(d1、d28、d56).
Study: NCT06647602

Intervention type: DRUG
Intervention: Euthyrox (levothyroxine)
Description: Euthyrox (levothyroxine sodium tablets; L-T4) is a thyromimetic synthetic drug identical to T4. Patients will recieve levothyroxine (euthyrox) in a dose of 2 μg × kg body weight / day.

Intervention type: DRUG
Intervention: Cytomel (liothyronine)
Description: Cytomel (liothyronine sodium tablets; L-T3) is a thyromimetic synthetic drug identical to T3. The pharmacoequivalent ratio of L-T3 to L-T4 is 1:3. The L-T4-cohort receive doses of 2 μg × kg body weight / day. The pharmacoequivalent L-T3 dose would be 1/3th of that namely: 0.67 μg × kg body weight / day. Cytomel will be given trice daily and available dosages are 5, 12.5 and 25 μg.
Study: NCT04988022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: 300 mg prefilled syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dupilumab
Description: 300 mg prefilled syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT04675515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Tobacco Treatment
Description: Bi-weekly tobacco treatment counseling and regular carbon monoxide monitoring
Study: NCT06471036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Champion Intervention
Description: The care champion will communicate with the patient according to an algorithm and will emphasize adherence to appropriate lipid lowering therapy, LDL-C retesting, and outpatient follow-up. The care champion will also facilitate communication of any challenges or issues with the patient's outpatient care team. Of note, the care champion will NOT be responsible for prescriptions or drug management.
Study: NCT04739722

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ColoSense
Description: ColoSense is intended for the qualitative detection of colorectal neoplasia-associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is for use with the ColoSense Collection Kit, the ColoSense Test Kit, the ColoSense Software, and the following instruments: Polymedco iFOBT Analyzer; bioMérieux EMAG Nucleic Acid Extraction System; and Bio-Rad QXDx ddPCR System. ColoSense is a single-site test performed at Geneoscopy, Inc.~A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at typical average-risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.
Study: NCT06067399

Intervention type: DIAGNOSTIC_TEST
Intervention: Glycated hemoglobin (HbA1C)
Description: Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )

Intervention type: DIAGNOSTIC_TEST
Intervention: Glycated hemoglobin (HbA1C)
Description: Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )

Intervention type: DIAGNOSTIC_TEST
Intervention: RDW
Description: Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )

Intervention type: DIAGNOSTIC_TEST
Intervention: RDW
Description: Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )

Intervention type: DIAGNOSTIC_TEST
Intervention: Lipid profile
Description: Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )

Intervention type: DIAGNOSTIC_TEST
Intervention: Lipid profile
Description: Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
Study: NCT06186817

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascial Distortion Model
Description: The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rocabado's 6x6 Exercises
Description: Resting position of the tongue, rotational control of temporomandibular joint, rhythmic stabilization, axial extension of the neck, shoulder posture, and stabilized head flexion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rocabado's 6x6 Exercises
Description: Resting position of the tongue, rotational control of temporomandibular joint, rhythmic stabilization, axial extension of the neck, shoulder posture, and stabilized head flexion

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education
Description: Participants are instructed to perform some behaviors while avoiding others based on the etiology of temporomandibular disorders.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education
Description: Participants are instructed to perform some behaviors while avoiding others based on the etiology of temporomandibular disorders.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Core Stabilization Training
Description: Week 1st (1 x 10 reps): Supine deep cervical activation, supine deep lumbar activation, prone deep cervical activation, prone deep lumbar activation, supine combined deep cervical and lumbar activation, and prone combined deep cervical and lumbar activation; Week 2nd (1 x 10 reps): Arm openings, hundreds 1, one leg stretch 1, double leg stretch 1, shoulder bridge, breaststroke, leg pull prone prep 1; Week 3rd (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 2, shoulder bridge, breaststroke, leg pull prone prep 2; Week 4th (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 3, shoulder bridge, breaststroke, leg pull prone prep 2; Week 5th to 8th (with Resistance Band; 1 x 10 reps): Arm openings, shoulder bridge, swan dive, scapula isolations, plough, biceps curl, roll up, roll up with biceps, roll up with rowing, seated spine twist, swimming in kneeling, one leg kick in kneeling and diamond press in standing
Study: NCT06407661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disaster Nursing course/education
Description: In this study, the Disaster Nursing course, which was integrated into the nursing curriculum, was an elective course, and it was carried out as a theoretical course for two hours a week. The topics in the content of this course regarding prevention, preparedness, response and recovery stages were designed in line with Jennings Disaster Nursing Management Model. The purpose of its development was to educate students on disaster management and disaster nursing. The course content included identification of risks and resources for disasters at the primary protection level, nurse's caregiver (triage and holistic care) and case manager role at the secondary protection level, reassessment of individuals' care needs at the tertiary level, and review of education and the current disaster plan at the protection level.
Study: NCT05129137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nefopam hydrochloride 30mg X2
Description: nefopam hydrochloride 30mg X2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nefopam hydrochloride 30mg X2
Description: nefopam hydrochloride 30mg X2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol 500 mg X2
Description: paracetamol 500 mg X2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol 500 mg X2
Description: paracetamol 500 mg X2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2
Description: Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2
Study: NCT05380544

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy
Description: ESWT will be given at 0.1mJ/mm2, 5 pulses/second and penetration of 5mm. Each intervention will be delivered in 3x30minute sessions over 7 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy
Description: ESWT will be given at 0.1mJ/mm2, 5 pulses/second and penetration of 5mm. Each intervention will be delivered in 3x30minute sessions over 7 days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy
Description: ESWT will be given at 0.1mJ/mm2, 5 pulses/second and penetration of 5mm. Each intervention will be delivered in 3x30minute sessions over 7 days.
Study: NCT05036668

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cryptosporidium parvum oocysts (ABO809)
Description: ABO809 3x10\^6 CE/3mL concentrate for oral suspension, single dose at Day 1
Study: NCT05731037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training for knee extensors
Description: The exercise will be started at 60% of 1 repetition maximum (RM) and progressed to 75% of 1 RM during the first 3 weeks and maintained throughout the intervention period. The exercise will be performed slowly (6 s/ repetition).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training for knee extensors
Description: The exercise will be started at 60% of 1 repetition maximum (RM) and progressed to 75% of 1 RM during the first 3 weeks and maintained throughout the intervention period. The exercise will be performed slowly (6 s/ repetition).
Study: NCT06561464

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EzPAP®
Description: EzPAP® is a portable, single-use respiratory exercise device that provides positive expiratory pressure during expiration while supporting respiration during inspiration. Its use has been increasing in recent years as an oxygenation device. It is portable, single-use, easy to use, well-tolerated, and cost-effective. EzPAP® helps increase functional capacity in the lungs and reduces atelectasis. With EzPAP®, an oxygen flow of 5-8 L/min reaches the patient as 35-42% fractionated oxygen, thus quadrupling the oxygen flow.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive mechanical ventilation (NIMV)
Description: NIMV provides respiratory support during both expiration and inspiration through continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP). Treatment success can be monitored within the first 2 hours by the improvement in oxygenation and reduction in pCO2 levels
Study: NCT06449001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Participants will receive danicopan on a weight-based dosing regimen.
Study: NCT04018456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: Biodentine is calcium silicate based cement which is bioactive and inductive material. Biodentine will be applied as coronal plug material.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White MTA
Description: MTA is calcium silicate based cement which is bioactive and inductive material. MTA is used in most cases of regenerative endodontics and it will be applied as coronal plug material.
Study: NCT05547295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Numeric prevention
Description: Numeric information for prevention of pressure sores thgrough digital tool MEDIASCREEN

Intervention type: OTHER
Group type: OTHER
Intervention: Paper prevention
Description: Information for prevention of pressure sores in classic way with paper
Study: NCT06329687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrvaya Nasal Pump
Description: Tyrvaya Nasal Pump with Silicone Lubricant
Study: NCT05138276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Umbilical Cord Blood Mononuclear Cells Therapy
Description: Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of NEC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: 0.9% Sodium Chloride in control group
Study: NCT05246189

Intervention type: OTHER
Intervention: Telephone Call
Description: Eligible subjects will be pre-selected by the study investigators on the basis of the medical file. A letter of information about the study will be sent to all the pre-selected eligible patients, with the exception of patients who have expressed an objection to the processing of their data for research purposes during their treatment.~The investigators will contact eligible patients by telephone approximately 2 weeks after the mailing of the information letter. During this telephone call, the investigator will answer any questions the patient may have about the study and will collect the patient's non-objection to participate in the study and their responses to the questionnaire.
Study: NCT04940182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC221
Description: Participants will receive XC221 100 mg 2 times a day during 14 full days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo 2 times a day during 14 full days